Trophoblast glycoprotein, also known as 5T4, is widely expressed in several solid tumors; cluster of differentiation 47 (CD47) is an ubiquitous immune checkpoint receptor that is also overexpressed in many solid tumors as well as in hematological cancers. A Yuhan Corp. research team has presented preclinical results on YH-38560, a bispecific fusion protein that targets both 5T4 and CD4 for the potential treatment of solid tumors.
Scientists at USA Elixiria Biotech Inc. and colleagues described data from preclinical studies evaluating the potential of the peroxisome proliferator-activated receptor γ (PPARγ) agonist, ELB-00824, for protection against chemotherapy-induced neuropathic pain (CINP).
Spectrum Pharmaceuticals Inc. president and CEO Tom Riga said the company would "immediately deprioritize" its poziotinib program after the U.S. FDA issued a complete response letter (CRL) suggesting the company would have to generate new clinical data prior to potential approval.
Voronoi Inc. has identified heteroaryl compounds acting as HER2 (erbB2) and/or HER4 (erbB4) inhibitors reported to be useful for the treatment of cancer.
Nuvation Bio Inc. has disclosed drug conjugates comprising a nuclear receptor-targeting moiety covalently linked to a poly(ADP-ribose) polymerase 1 (PARP1) and/or PARP2 inhibitor though a linker. They are reported to be potentially useful for the treatment of cancer.
Merck KGaA and Cancer Research Technology Ltd. have synthesized 2,8-dihydropyrazolo[3,4-b]indoles acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, cardiovascular disorders and liver fibrosis.
Regulatory T cells (Tregs) are known suppressors of immunity activation in the tumor microenvironment, and a high density of Tregs is tied to a poor response to cancer immunotherapy, with CCR8+ Tregs identified as being highly suppressive. Ctm Bio Co. therefore have studied the CCR8 antagonist antibody CTM-033 in preclinical cancer models.
Killer cell immunoglobulin-like receptor 3DL3 (KIR3DL3) is a member of the killer cell Ig-like (KIR) receptor family. When KIR3DL3 is expressed on T and natural killer (NK) cells in the tumor microenvironment, it suppresses immune responses following engagement with HHLA2, suggesting that the KIR3DL3-HHLA2 axis potentially represents a novel immune checkpoint pathway and that blockade of KIR3DL3 signaling could promote antitumor immunity.
Chengdu Easton Biopharmaceuticals Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) ligand binding moiety covalently bound to a bromodomain-containing protein 4 (BRD4; HUNK1)-targeting moiety through a linker.
RSS
